A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
- 12 September 2024 - 1 mins read
Study aimed at comparing the pharmacodynamic profile (including duration of action) of three commercialized toxins by measuring the action potential of the injected muscle (extensor digitorum brevis)
Related Clinical Trials
12 September 2024
1 mins read
An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in People With Fibrodysplasia Ossificans Progressiva (FOP) in France
12 September 2024
1 mins read
Evaluation of Palovarotene Concentration in Semen of Healthy Men after Multiple Oral Doses
12 September 2024
1 mins read
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
12 September 2024
1 mins read
A Thorough QT Study Evaluating the Effect of a Therapeutic and a Supratherapeutic Dose of Palovarotene on Electrocardiogram Parameters
12 September 2024
1 mins read
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in...
12 September 2024
1 mins read
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
12 September 2024
1 mins read
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
12 September 2024
1 mins read
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
12 September 2024
1 mins read
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
12 September 2024
1 mins read